Thursday, 29 November 2018 18:45

Anticoagulation news items. Week commencing 26th November 2018

Early Risks of Death, Stroke/Systemic Embolism and Major Bleeding in Patients with Newly Diagnosed Atrial Fibrillation: Results from the GARFIELD-AF Registry


Registry study (n=52,014) found an elevated mortality rate in the first month after diagnosis vs the first year (6.8 vs 4.3 100 person years for first month and first year respectively). The elevated 1-month mortality rate was mostly attributable to cardiovascular mortality.


Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial

The Lancet Respiratory Medicine

RCT (N=105) reported an improvement from baseline in mean 6-min walk distance in the treprostinil high and low dose groups (44·98 m and 4·29 m; p=0·0016). Treprostinil is an investigational prostacyclin analogue that has received orphan drug status in the EU.




The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: